All In Biotech

Drug Trial Radar · NCT02125721

Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria

Last checked: Nov 19, 2026Latest source record: Aug 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Jun 2012

Primary completion

Dec 2017

Study completion Dec 2017

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
Apr 29, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.

Conditions

  • Cystinuria

Interventions

  • Tiopronin 1g per dayDrug

    500mg PO BID x 7 days

  • Tiopronin 2g per dayDrug

    1g PO BID x 7 days

  • Tiopronin 3g per dayDrug

    1.5g PO BID x 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cystine CapacityTime frame: 4 weeks on assigned therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NYU Langone Medical Center

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.